Sanofi (NASDAQ:SNY) Receives Average Rating of “Hold” from Brokerages

Sanofi (NASDAQ:SNY) has earned an average recommendation of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $51.00.

Several equities analysts recently weighed in on the stock. Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Finally, Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently made changes to their positions in SNY. Flagship Harbor Advisors LLC purchased a new position in shares of Sanofi in the 4th quarter worth $25,000. Physician Wealth Advisors Inc. grew its stake in shares of Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after buying an additional 379 shares in the last quarter. Leonteq Securities AG grew its stake in shares of Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares in the last quarter. Western Wealth Management LLC purchased a new position in shares of Sanofi in the 1st quarter worth $29,000. Finally, Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi in the 3rd quarter worth $29,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY opened at $42.38 on Friday. The stock has a market capitalization of $102.75 billion, a price-to-earnings ratio of 11.84, a PEG ratio of 1.05 and a beta of 0.34. The company has a fifty day moving average of $44.79 and a 200 day moving average of $46.33. Sanofi has a fifty-two week low of $41.85 and a fifty-two week high of $52.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were paid a dividend of $2.4225 per share. The ex-dividend date of this dividend was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s dividend payout ratio is 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.